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Purpose: Hyphema is a sequela of ocular trauma and can be associated with significant morbidity. Management of this condition is
variable and can depend on individual institutional guidelines. We aimed to summarize current practices in hyphema management
across ophthalmological institutions worldwide.
Methods: A cross-sectional online survey was conducted across North America, Asia, South America, Africa, Europe, and Australia
from August 2020 to January 2021. The survey assessed the existing practices in the management of hyphema at each institution.
Results: For layered hyphema, topical steroids were routinely administered by 34 (of 36 respondents, 94.4%) institutions, of which
prednisolone was the preferred choice (n = 32, 88.9%). Topical cycloplegics were used at 34 (94.4%) institutions. No institution
reported routine use of antifibrinolytics. Head elevation was the most deployed procedure to promote hyphema reabsorption (n = 31,
86.3%), followed by partial bed rest (n = 21, 58.3%). The majority of institutions (n = 25, 69.4%) did not routinely pursue admission
for hyphema patients, although 75.0% of institutions (n = 27) scheduled follow-up visits within 48 hours of presentation. Additionally,
few institutions performed routine sickle cell trait testing for patients presenting with hyphema (n = 6, 16.7%). The decision to perform
anterior chamber washout varied and was often based on intraocular pressure and the speed of hyphema resolution.
Conclusion: Unanimity of international institutions on hyphema management is lacking. As it stands, many current interventions
have unconvincing evidence supporting their use. Evidence-based guidelines would be beneficial in guiding decision-making on
hyphema management. Additionally, areas of consensus can be used as foundations for future standard of care investigations.
Keywords: current practices, hyphema, trauma, sickle cell, anterior segment

Introduction
Hyphema consists of blood build up in the anterior chamber (AC) of the eye resulting from injury to ciliary body and iris
blood vessels.1 Hyphema most often occurs after trauma or surgery, but may also arise spontaneously due to coagulo
pathies, neovascularization, or sudden intraocular pressure changes.1,2
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The level of hyphema is one of the critical factors for grading its severity, in addition to corneal blood staining and
intraocular pressure.3 The mildest grade of hyphema is termed microhyphema, which consists of red blood cells in the
AC that are only identifiable via microscopy and/or gonioscopy.4 When a hyphema progresses and erythrocytes
precipitate, it is considered to be a gross or layered hyphema, which is graded based upon the extent to which
erythrocytes fill the AC.4
In cases of traumatic ophthalmic injuries that induce hyphema, poor visual outcome (ie, <20/40) is often due to
associated injuries (such as corneal laceration or retinal detachment), but can be due to the hyphema itself in 8–33% of
cases.2 Current treatment regimens for hyphema include cycloplegics, steroids, antifibrinolytics, and non-steroidal antiinflammatory medications, as well as activity restrictions, such as partial to complete bed rest, and protection with a rigid
shield.2
While various studies have investigated the comparative efficacy of specific interventions for hyphema management,
uncertainties persist regarding which medications and interventions are optimal.1 The American Academy of
Ophthalmology (AAO) provides recommendations on management standards for many common conditions in ophthal
mology called the Preferred Practice Patterns©.5 However, these guidelines do not cover most traumatic ocular injuries,
including hyphema. Additionally, inconsistencies in traumatic hyphema treatment likely persist given the heterogeneity
of institutional resources on an international level.
We surveyed ophthalmic trauma experts at international institutions to summarize generally accepted principles of
hyphema management and to highlight areas of variation within clinical practice.

Methods
The development of this survey was described previously.6,7,31 Briefly, there were 123 questions in the survey, with
21 pertaining to the treatment of hyphema using medications, surgical interventions, and activity modifications. The
hyphema-related survey questions are included in Supplemental Document 1. Respondents were advised to provide
answers that reflect the management protocols at their respective institutions collectively rather than individual partial
ities. This study was deemed exempt by the Institutional Review Board at the Johns Hopkins School of Medicine due to
the low risk posed to participants. Study activities observed the tenets of the Declaration of Helsinki and laws in the state
of Maryland.
Email invitations for the survey were sent to experts in ophthalmic trauma who were members or affiliates of the
American Society of Ophthalmic Trauma (ASOT) or the Asia Pacific Ocular Trauma Society (APOTS) and to the
members of the International Globe and Trauma Epidemiology Study (IGATES). Invitees were reminded by email up to
three times to complete the survey.
Data analysis was completed using Microsoft Excel (Microsoft Inc., Redmond, WA, USA), Stata (StataCorp, College
Station, TX), and GraphPad Prism (GraphPad Software, San Diego, California, USA). Significant differences (p < 0.05)
in proportions of responses were determined by Student’s t-test and chi-squared tests. Data were shown as percentages of
all responses and exceptions were noted. For responses that included numerical ranges, the range mean was used.

Results
Characteristics of Responding Experts and Institutions
Responses from 37 institutions (response rate = 88.1%) were received; of which, one (2.4%) was excluded because the
survey was not finished (Table 1). Locations and characteristics of respondents are outlined in Table 1.
The approximate volume of hyphema cases managed per year at each institution is shown in Table 1. Four responding
experts (11.1%) were unable to estimate the caseload of patients with hyphema at their respective institutions. Sub-group
analyses were completed to identify whether differences in practice paradigms exist between institutions where the
caseloads of hyphema were known versus not known, and between experts at low-volume versus high-volume centers
(<50 and 50+ cases per year, respectively, Supplemental Tables S1 and S2); these stratifications did not lead to any
statistically significant differences in practices observed.
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Table 1 Summary of Respondents and Institutional Characteristics
Response Selection (N = 42)
Responses Included in Analysis (N, %)

36 (85.7%)

Non-Respondents (N, %)

5 (11.9%)

Partial Responses (N, %)

1 (2.4%)

Respondent Location and Experience (N = 36)
Location of Institution
Africa (N, %)

3 (8.3%)

Asia (N, %)
Australia (N, %)

13 (36.1%)
1 (2.8%)

Europe (N, %)

2 (5.6%)

North America (N, %)
South America (N, %)

13 (36.1%)
4 (11.1%)

Years practicing post-residency (avg. ± s.d.)

14.81 ± 8.23

Institutional Parameters (N = 36)
Eye ED at Institution (N, %)

20 (55.6%)

Center is Designated for Trauma (N, %)

20 (55.6%)

In-House Ophthalmology Coverage Available at All Times (N, %)
Ophthalmologist Available on Hour Notice (N, %)a

26 (72.2%)
10 (100.0%)

No. of Patients Presenting with Hyphema at Responding Institutions per Year (N = 36)
0–50

12 (33.3%)

51–100
101–150

7 (19.4%)
7 (19.4%)

151–200

4 (11.1%)

201+
Unknown

2 (5.6%)
4 (11.1%)

Note: aProportion of respondents without in-house coverage (n = 10).
Abbreviations: ED, emergency department; avg, average; s.d, standard deviation.

Medication Protocols for Hyphema Management
There was no significant difference in the frequency of administering topical steroids for gross versus microhyphema,
with 94.4% of experts (n = 34) routinely administering steroids for gross hyphema and 80.6% (n = 29) for microhyphema
(p = 0.079, Table 2). Prednisolone was the most used steroid for both hyphema types.
Most respondents (n = 34, 94.4%) administered topical cycloplegics for all patients presenting with hyphema. Of
these, atropine 1% was the most preferred (n = 21, 58.3%), followed by cyclopentolate 1–2% (n = 13, 36.1%
Table 3). Three of the experts who selected “other” wrote in tropicamide (8.3%), while two others wrote in
Table 2 Preferences for Steroid Use in the Management of Different Types of Hyphema

Routinely Administer Topical Steroids
Prednisoloneb
Dexamethasoneb
Difluprednateb
Typical Steroid Duration (days ± s.d.)
a

c

Gross Hyphema (N, %)

Microhyphema (N, %)

P-value

Total N

34 (94.4%)a

29 (80.6%)a

0.079

36

32 (88.9%)
6 (16.7%)

25 (69.4%)
3 (8.3%)

N/A

36

0 (0.0%)

1 (2.8%)

17.8 ± 9.6

13.7 ± 8.3

0.093

36

b

Notes: One respondent selected “Do not know” for each gross and microhyphema, respondents were able to select more than one
response, for gross hyphema steroid preference, one respondent wrote in “prednefrin forte or maxidex”, and for microhyphema, one expert
wrote in “lotepred”, cduration includes tapering of doses, two institutions responded that duration varies or was until resolved, one indicated
duration depended on grade.

Clinical Ophthalmology 2022:16

https://doi.org/10.2147/OPTH.S372273

DovePress

Powered by TCPDF (www.tcpdf.org)

3137

Dovepress

Miller et al

Table 3 Other Medication and Dispositional Preferences for the Management of
Hyphema
N=36

All Hyphema (N, %)

Routinely administer topical cycloplegicsa

34 (94.4%)

Atropine 1%

21 (58.3%)

Cyclopentolate 1–2%
Otherb

13 (36.1%)
7 (19.4%)

Do not administer antifibrinolytics

36 (100.0%)

Routinely discontinue anticoagulation or anti-platelet medicationsc

15 (41.7%)

Activity modificationsd
Elevate head and sleep upright
Partial bed rest

31 (86.1%)
21 (58.3%)

Shielding of eye

19 (52.8%)

Complete bed rest
Minor activity limitations

8 (22.2%)
6 (16.7%)

Othere

1 (2.8%)

No activity limitations

0 (0.0%)

Routinely screen for sickle cell disease/trait

6 (16.7%)

Routine disposition of hyphema patients
Admitted to hospital

8 (22.2%)

Discharged without admitting
Otherf

25 (69.4%)
3 (8.3%)

Notes: aOne respondent selected “Do Not Know”, bother responses included homatropine, tropicamide (±
phenylephrine), variable, cif deemed safe by primary care provider, other responses included depending on PCP
advice, in patients with significant rebleeds, depending on the reason for anticoagulation, and that the decision is
highly variable, drespondents could select more than one option, eother response stated that activity limitation
depended on grade, fother responses included depending on IOP and blood amount.

homatropine (5.6%). Additionally, two experts (5.6% of all respondents) indicated cycloplegic selection was
contingent on the age of the patient, their injury characteristics, and insurance coverage. No responding experts
reported administering antifibrinolytics for hyphema (n = 0, 0.0%, Table 3). Fewer than half (n = 15, 41.7%) attested
to discontinuing anticoagulation or anti-platelet medications if deemed appropriate by the patient’s primary care
provider (PCP, Table 3).

Activity Limitation Protocols
While all responding experts routinely recommended limiting the activity of hyphema patients to at least some degree (n = 36,
100%), we observed variation in what limitations were routinely advised; 86.1% of experts routinely advised patients to
elevate their head and sleep upright (n = 31), and 58.3% of experts restricted patients to partial bed rest (n = 21), while 22.2%
required complete bed rest (n = 8). Around half (n = 19, 52.8%) recommended shielding of the eye, while 16.7% required
minor activity limitations (n = 6).

Screening for Sickle Cell Disease or Trait in Hyphema Patients
Approximately 16.7% of responding experts routinely screened all patients presenting with hyphema for sickle cell
disease or trait (SCD/T, n = 6, Table 3), while 11.1% (n = 4) did not screen patients with only this presentation. Of those
who did routinely screen for SCD/T, 2 centers were in Asia, 2 were in North America, 1 in Africa, and 1 in South
America. The remaining survey respondents (n = 26, 72.2%) completed screening for SCD/T if certain indications were
present (Figure 1), such as certain race or ethnicity (50.0%, n = 18), family history (13.9%, n = 5), and high IOP (n = 2,
5.6%). Information on indications for SCD/T screening was not provided by 3 respondents (8.3%).
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Figure 1 Indications for which screening for sickle cell disease/trait was performed in patients presenting with hyphema. Common races and ethnicities cited as potential
indications for screening include African, Mediterranean, and Tharu descent. Percentages were shown as proportions of all respondents (n = 36). Three respondents who
screened for certain patients did not provide indications. IOP = intraocular pressure.

Indications for Surgery in Patients with Hyphema
SCD appeared to affect the conditions under which the experts performed AC washouts in patients with hyphema. Many
respondents had a lower threshold for surgical intervention when IOP was elevated in patients with SCD compared to
patients without SCD. Specifically, 30.6% of experts (n = 11) reported performing AC washouts in patients with SCD
when their IOP was greater than 24 mmHg for 1–2 days, while only 5.6% of experts (n = 2) performed the washout in
patients without SCD with this indication. Rather, IOP >50 mmHg for two to five days was a commonly cited threshold
to perform AC washouts in patients without SCD (16.7%, n = 6, Table 4). IOP criteria and thresholds for performing AC
washouts in patients with and without SCD are summarized in Table 4.
In terms of other indications for AC washout aside from elevated IOP, 8.3% of respondents (n = 3) performed AC
washouts in all patients with hyphema and SCD as soon as possible, while only 2.8% of respondents did so in patients
without SCD (n = 1, Table 4). A summary of indications aside from IOP thresholds for performing AC washouts is
shown in Table 4.

Disposition for Patients with Hyphema
Patients with hyphema alone were not usually admitted to the hospital by 69.4% of experts (n = 25), while 22.2%
routinely admitted them to the hospital for monitoring (n = 8). However, 8.3% of respondents (n = 3) indicated that
admission practices were highly variable and dependent on the amount of blood present as well as intraocular pressure.
The expected schedule of follow-up visits per center is shown in Figure 2.

Discussion
The data reported here highlight that the controversies previously described in hyphema management currently persist
internationally.1 Although we witnessed several areas of general consensus, including the use of topical steroids and
cycloplegics, and the recommendation for head elevation/sleeping upright, we observed areas of variation in preferences for
the administration and types of medications used for hyphema cases, indications for surgical interventions, as well as
activity limitations and typical disposition of patients. Previous investigations thus far have shown management techniques
to affect secondary hemorrhage rates, but not necessarily improve visual outcomes.1,2,8,9,32 However, evidence-based
management protocols are still needed to reduce clinical waste, limit unnecessary exposure to medication side effects or
adverse surgical events, and ensure access to optimal care.
Steroids are widely considered a mainstay of hyphema treatment to prevent rebleeds and synechiae formation,2,10,11
but there is conflicting evidence for their effectiveness in this setting. Several controlled prospective studies found no
association between systemic steroid use, particularly prednisone, and the incidence of secondary hemorrhage or final
visual outcomes after traumatic hyphema.12,13 More recently, a systematic review was unable to determine efficacy due
to a lack of statistical power in existing trials.11 In another meta-analysis, however, steroids (either topical or systemic)
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Table 4 Indications for Performing an Anterior Chamber Washout in Patients with Hyphema with
and without Sickle Cell Disease
Criteria, N (%)a

Patients with SCDb

Patients without SCD

Uncontrolled for >1-2 days

3 (8.3%)

6 (16.7%)

>60 for 2 days
>50 for 2–5 days

0 (0.0%)
0 (0.0%)

3 (8.3%)
6 (16.7%)

>40 for 2 days

1 (2.8%)

1 (2.8%)

>35 for 5–7 days
>35-40 at any point

0 (0.0%)
0 (0.0%)

2 (5.6%)
2 (5.6%)

>30-35 for 2+ days
>30 at any point

4 (11.1%)
3 (8.3%)

4 (11.1%)
3 (8.3%)

>24 for 7+ days

0 (0.0%)

1 (2.8%)

>24 for 3–5 days
>24 for 1–2 days

2 (5.6%)
11 (30.6%)

4 (11.1%)
2 (5.6%)

>24 at any point

2 (5.6%)

1 (2.8%)

As soon as possible

3 (8.3%)

1 (2.8%)

Corneal blood staining
Not improving >1 week

2 (5.6%)
1 (2.8%)

8 (22.2%)
6 (16.7%)

Large or complete hyphema

2 (5.6%)

3 (8.3%)

Complete hyphema for 3–5 days
Physician or case-dependent

1 (2.8%)
1 (2.8%)

1 (2.8%)
4 (11.1%)

Do not see sickle cell cases

6 (16.7%)

0 (0.0%)

IOP Indications

Other Indications

a

b

Notes: Respondents could provide more than one indication, two institutions did not provide indications for patients with
SCD. SCD = sickle cell disease.

were found to effectively reduce secondary hemorrhage risk, but not to improve final visual acuity.2 Other trials have
found that systemic and/or topical steroids may be beneficial for preventing rebleeds.8 Despite a lack of conclusive
evidence, the vast majority of experts in our study routinely administered topical steroids to patients with gross hyphema
or microhyphema (n = 34, 94.4%, and n = 29, 80.6%, respectively). Because topical steroids have limited side effects
compared to systemic administration, they would be preferred if they are found to be similarly effective. Investigations
are needed to compare the efficacy of topical steroids relative to control groups without steroid treatment and to systemic
therapy to determine if topical steroids alone are sufficient, as well as determine an optimal dosing regimen.
Cycloplegics in the setting of hyphema have been shown to reduce pain resulting from iritis and ciliary spasm,
prevent synechiae formation, and improve visualization of posterior eye structures.1 Several studies have shown
cycloplegics to have no effect on preventing secondary hemorrhage or improving visual outcomes in patients with
hyphema.1,14 A preventative effect of cycloplegics on rebleeding was found in only one study in patients who were also
using aspirin.15 However, the use of topical cycloplegics was popular among survey respondents (n = 34, 94.4% routinely
administered), with the most commonly used being atropine 1%. This may be due to the aforementioned benefits,
including reduction of pain and improved visualization of the posterior segment. Clarification is needed on possible
detrimental effects of cycloplegics on hyphema, as well as to ascertain benefit to their use.
A review of studies on hyphema management found antifibrinolytics tranexamic acid and ϵ-aminocaproic acid to be
associated with moderately lower rates of rebleeding than control groups.2 This effect has potential benefits for patients,
as rebleeds of hyphema are more likely to necessitate surgical intervention than primary hyphema.16 However, a more
recent review has found no evidence that administering antifibrinolytics led to improved long-term outcomes including
improved visual acuity after hyphema.11 Additionally, systemic antifibrinolytics incur the risk of clotting elsewhere in the
body, and are contraindicated in patients with a history of thromboembolism.17 The topic of antifibrinolytic
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Figure 2 Follow-up visit schedules for patients with uncomplicated hyphema at each responding institution (for example, the patient could follow up daily for 5 days after
presentation). Institutions are separated on the vertical axis. If no end date was given for follow-up, it was assumed that patients were followed until resolution of the
hyphema. If a range of days were provided, the average was used for visualization. *Resolution may occur before 25 days.

administration generated a consensus among the experts we surveyed, who agreed on a preference to not administer
antifibrinolytics for patients presenting with hyphema.
We observed more controversy around discontinuing anticoagulation/anti-platelet medications in patients presenting
with hyphema. Approximately 41.7% of experts (n = 15) in our study attested to routinely stopping these therapies if
deemed safe by the patient’s PCP. Although there is a paucity of investigations exploring the role of discontinuing
anticoagulation/anti-platelets in the management of traumatic hyphema, a study of these medications taken prior to and at
the time of glaucoma surgery demonstrated a higher risk of post-operative hyphema.18 For this reason, around one-third
of ophthalmologists surveyed stopped pro-bleeding therapies prior to glaucoma surgery.19 Further investigations into the
risks and benefits of hemostasis-related medications in the setting of hyphema and their effects on long-term visual
outcomes are needed to clarify optimal standards of care.
Another clinical consideration for patients with hyphema is the care of those with hemoglobinopathies. In particular,
patients with SCD have a significantly increased risk of developing rebleeds, increased IOP, and non-resolving visual
impairment because of hyphema.20 In these patients, red blood cells are prone to sickling in the AC and face greater
resistance in passing through the trabecular meshwork, leading to increased intraocular pressures.21 It is therefore crucial that
patients with hyphema and SCD are identified, monitored, and when appropriate, treated more aggressively. In fact, 16.7% of
centers that responded to our survey screened all patients who presented with hyphema for this gene alteration. However, this
may have been impacted by the relative prevalence of SCD/T in certain groups in the populations seen by the responding
centers. For example, in the US, it has been estimated that 15.5 of 1000 newborns and 73.1 of 1000 Black newborns are
identified to have SCT annually.22 Nine of 10 centers in the US screen for SCD/T if the patient presenting with hyphema
identifies as Black or of African descent. One investigation recommended screening patients with microhyphema of African
or Hispanic descent who had intraocular pressures greater than 21 mmHg because it was at this threshold that treatment
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would be more intensive.23 There are no prospective randomized studies regarding the indications for screening for SCD/T
and further guidelines are needed to determine the scenarios in which screening for this allele is warranted.
SCD/T status not only impacts medication management decisions, but also thresholds for surgical interventions.
Surgical interventions for hyphema are usually a last resort.2 One study that compared the medical and surgical
treatment of hyphema found that the medically treated group had better final visual acuity while the surgically treated
group had faster resolution.24 Surgical treatment has been associated with adverse effects such as bleeding and
damage to the lens capsule or corneal endothelium.25 Hence, surgery is generally reserved for patients who are at
meaningful risk for developing sight-threatening complications of hyphema. The criteria proposed by Read in 1975
are often used to determine when surgical management of hyphema is necessary. They are: i) presence of corneal
blood staining, ii) total hyphema and IOP >50 mmHg for 5 days, ii) total hyphema that has not resolved by at least
50% after 5 days with IOP >25 mmHg, and iv) hyphema that has not cleared after 9 days.26,27 Deutsch et al proposed
lower thresholds for surgical intervention in patients with SCD/T, including IOP >24 mmHg for 24 hours, or multiple
transient pressures >30 mmHg.28 Respondents to our survey were generally more proactive than published recom
mendations in proceeding with surgery for patients without SCD. Twelve experts (33.3%) indicated that their
institution would proceed with AC paracentesis if the patient’s IOP is >40 mmHg for approximately 2 days.
Contrarily, respondents were more lenient with the IOP of patients with SCD; only 30.6% of responding experts
(n = 11) adhered to the guideline of surgery when IOP was >24 mmHg for 1–2 days, while 27.8% of experts allowed
SCD/T patients to reach higher IOPs or for longer periods of time (n = 10, Table 4).
In previous investigations, clots were shown by pathology to be well-formed and to retract from the iris at four days
post-injury in hyphema patients.25,29 It was then hypothesized in these studies that disrupting the clots before this time
point may disrupt healing of the vasculature.25 However, it was observed that delaying surgery past 8 days after
presentation with hyphema was associated with the possible development of optic atrophy.30 It is notable, though, that
most studies preceded the use of optical coherence tomography to sensitively detect retinal ganglion cell degeneration or
modern automated perimetry to detect functional deficits.30 Due to the variation in indications we observed for
performing AC taps in patients with hyphema, and the potential for time sensitivity of surgical interventions, further
studies are needed to determine if and when surgery for hyphema should be performed.
Follow-up regimens were also highly variable, although three-quarters of experts conducted a first review within 48
hours of presentation. We did not investigate the rationale behind follow-up intervals, but a likely justification is the
perceived likelihood and severity of IOP elevation at different time points and the rapidity with which this must be
treated. Another consideration for timely follow-up is the rate of development of associated injuries such as retinal
dialysis. The fact that delayed access to care is associated with poor outcomes highlights the importance of these
decisions and the need for additional evidence.14
Several limitations exist when interpreting the results of this study. Firstly, in an effort to focus the survey,
respondents were not asked for their preferences on the use of systemic steroids for hyphema, which may have impacted
their preference for topical steroids or other management paradigms. Although there were no significant differences
found between low- and high-volume centers, as well as centers with known and unknown volumes of patients, these
estimated case volumes were based on physician reports rather than formal documentation. Additionally, while the study
team made every effort to distribute the survey broadly, the survey sample size is small, and responses are not
comprehensive geographically, limiting generalizability of these results. Similarly, survey invitees were members or
affiliates of ASOT and APOTS, which may bias the results of the population surveyed. Because the survey was given
exclusively in English, every attempt was made to write simple, plain-language questions; however, there remains
a possibility that the wording of specific questions could have been incompletely understood by non-native English
speakers. Lastly, despite explicit instruction for responding experts to provide responses that capture their institutional
policies, individual preference and recency bias may have skewed responses.
Despite these limitations, this investigation has several pertinent strengths. We comprehensively outlined international
practice patterns of hyphema management in ocular trauma centers. In doing so, we identified areas of variation that in
future studies can be evaluated for their impact on visual outcomes. This work lays the foundation for more streamlined,
evidence-based care for patients with hyphema compared to the current physician- and institution-level standards.
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